Bladder Cancer Treatment Guidelines

February 16, 2022

Clinical practice guidelines (or simply “guidelines”) are recommendations on how to diagnose and treat disease, like bladder cancer. They are mainly written for doctors, but also for nurses and other health care professionals. Guidelines are developed by experts after reviewing the research that improves the quality, effectiveness, and efficiency of cancer care.

Guidelines summarize current medical knowledge. Experts weigh the benefits and harms of diagnostic procedures and treatments. They give specific recommendations based on this information. They also provide information about the scientific evidence supporting those recommendations. Clinical guidelines are meant to help ensure that patients receive appropriate treatment and care.

Experts from the American Urological Association (AUA), the Society of Urologic Oncology (SUO), the American Society for Clinical Oncology (ASCO), the American Society for Radiation Oncology (ASTRO), the Society for Immunotherapy of Cancer (SITC), the National Comprehensive Cancer Network^® (NCCN^®), and the European Association of Urology (EAU) have developed guidelines for bladder cancer.

Access those guidelines at the links below:

• Microhematuria: AUA/SUFU Guidelines (2020)
• EAU Muscle-invasive and Metastatic Bladder Cancer (2022)
• Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Joint Guideline (2020)
• Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline (2020)
• NCCN Bladder Cancer Guidelines – for clinicians and the NCCN Bladder Cancer Guidelines – for patients.
• The SITC consensus statement on immunotherapy for the treatment of bladder carcinoma.
• NCCN Guidelines for Supportive Care (Includes managing pain, nausea, fatigue, and palliative care.)